

## SA COVID-19 POC STUDY- INFORMATION SHEET AND CONSENT FORMS

### FOR ASYMPTOMATIC CONTACTS

*One copy will stay with the study team for filing. A second copy will be given to the participant*

**TITLE: Investigating Point of Care Diagnostic Strategies to Optimise the Rapid Diagnosis of COVID-19 in routine public and private health care settings in South Africa  
(SA COVID-19 POC STUDY)**

#### **Principal Investigators:**

Dr. Ameena Goga - South African Medical Research Council (SAMRC) - 012 3398524

Prof. Glenda Gray - South African Medical Research Council (SAMRC) - 021 9380905

#### **INTRODUCTION**

You are invited to take part in a COVID-19 study called the South African COVID-19 point of care study or the SA COVID-19 POC study. This information leaflet gives you more information about this research study. Before you agree to take part in this study you should fully understand the study and what is required. If you have any questions - do not hesitate to ask us. You should not agree to take part unless you fully understand and are happy with all the procedures involved. You may choose not to take part in this study or leave this study at any time.

#### **WHY ARE WE DOING THIS STUDY?**

Like many countries in the world, South Africa is experiencing a COVID-19 pandemic, caused by the SARS-CoV-2 virus. This virus comes from a family of viruses called coronaviruses.

At the moment, the best way to detect SARS-CoV-2 is to conduct a test called real-time Reverse transcription polymerase chain reaction (RT-PCR). Whilst this test is accurate, the test can only be done in a laboratory by highly skilled laboratory staff, and the results take a long time to reach the person who wants to know if they are infected, or not. This test is also expensive.

This study focuses on investigating new rapid tests to detect infection with SARS-CoV-2. These new tests can be conducted in the community/clinics/hospitals by other health workers, besides laboratory staff. These new tests are quick and cheap, and results are available after approximately 5-30minutes, depending on the type of test used. We are doing this study to check whether these results are accurate. If we find that the rapid tests are accurate then we may be able to use them in the community to do mass COVID-19 testing. Mass testing is important to help us quickly identify who is infected, so they may be cared for, and isolated to prevent the spread of the virus to others. You are asked to take part in this study because you are a close contact of someone with COVID-19 disease, and you are not yet sick. We want to understand whether your test results will be positive even though you are not sick. This will help us understand COVID-19 disease better.

#### **EXPLANATION OF PROCEDURES TO BE FOLLOWED**

English: Study Informed Consent-Asymptomatic, Version 5.0 Dated: 31 March 2021

Based on Protocol: Investigating Point of Care Diagnostic Strategies to Optimize the Rapid Diagnosis of COVID-19 in routine public and private health care settings in South Africa- SA COVID-19 POC STUDY, Version 5.0, Dated: 31 March 2021  
Investigator Ameena Goga

Approved by: SAMRC Human Research Ethics Committee Approved on: 08 April 2021

We will collect information from you, such as your age and whether you are a male or female. We will also ask you how you are feeling today, any other illnesses you have and what treatment you are on. Some questions may be sensitive e.g. questions about whether you have HIV, TB, diabetes (sugar) and hypertension so that we can understand the relationship between these diseases and COVID-19. You may choose not to answer these questions.

We will be doing the following tests as part of the study:

1. **Finger prick COVID-19 rapid test:** We will prick you and do a rapid test(s) for COVID-19. The rapid test result(s) can be given to you, but it will not be your final confirmed COVID-19 result because the result(s) may be wrong. Your true COVID-19 test result will come from RT-PCR testing in the laboratory.
2. **Blood tests:** We will collect approximately **six teaspoons of blood in total** in special tubes.
  - In the **Western Cape in 100 people** we will take an **additional eight teaspoons** of blood to do additional tests on immune function because the laboratory that specializes in these tests is located in the Western Cape. We will send this to the laboratory for COVID-19 testing, including how the soldiers of the body (the immune system) respond to COVID-19.
  - We will also take **4 additional teaspoons of blood from a group of participants (or from all participants if budget allows)**, for more detailed tests to understand how the body responds to COVID-19.
3. **Nasal swab:** We will also collect one swab - for the routine test for virus in the laboratory. We may collect additional nasal swabs for genome analysis – this means to see what genes the virus has.
4. **Saliva sample:** We will also collect a saliva sample to test whether COVID-19 can be diagnosed using saliva. If you are tested positive, we may like to contact you again to collect additional samples at 3, 6, 9 and 12 months in order to understand how your immune system respond to COVID-19 over time. We will discuss further details with you if you agree for us to contact you. You can always choose not to take part in this follow-up study.

Any residual samples will be stored in a biorepository, so that we can do additional diagnostic testing as new tests become available, or so that we can test for antibodies and study other immune factors such as cytokines and white blood cells which assist in fighting the infection. Your samples will be stored under strictly controlled conditions and all of the data linking the data with your identity will be protected. It may become necessary to transfer some of the material to laboratories around the country but this will be under strict control. You will be able to withdraw your material from storage if you are concerned about this aspect.

#### **RISK AND DISCOMFORT INVOLVED.**

You might feel discomfort when the swab is taken and some pain when blood is taken. Taking blood rarely causes infection. The specimens will be taken by trained staff.

English: Study Informed Consent-Asymptomatic, Version 5.0 Dated: 31 March 2021

Based on Protocol: Investigating Point of Care Diagnostic Strategies to Optimize the Rapid Diagnosis of COVID-19 in routine public and private health care settings in South Africa- SA COVID-19 POC STUDY, Version 5.0, Dated: 31 March 2021  
Investigator Ameena Goga

Approved by: SAMRC Human Research Ethics Committee Approved on: 08 April 2021

**POSSIBLE BENEFITS OF THIS STUDY.**

You will learn if you are infected with COVID-19 or not. You will contribute to our knowledge about better testing methods for COVID-19.

**REIMBURSEMENT**

We will provide a reimbursement to the value of R150 for today's visit. This is for your time and any inconvenience.

**HAS THE STUDY RECEIVED ETHICAL APPROVAL?**

Yes, the study was approved by the SAMRC Human Research Ethics committee and abides by the Declaration of Helsinki (updated Oct 2008), which deals with the recommendations guiding doctors in biomedical research involving human/subjects.

**CONFIDENTIALITY**

Although we will use your name, ID number or hospital numbers to identify your samples and results, we will not use any information that can identify you, when the findings of the study are published.

Your personal information may however be disclosed if required by law or by the Department of Health.

**CONSENT FOR SAMPLE STORAGE**

Once testing for this study has been completed, there might be blood left over. We would like to store the remaining blood for future testing. Any future testing that will be done, will be approved by the Ethics Committee. If you choose not to give consent for the remaining blood to be stored for future studies, you may still continue with this study participation, and your blood will be discarded after testing for this study.

**STUDY WITHDRAWAL**

This study is voluntary, and you can withdraw at any round of testing. If you shows signs of distress at the time of taking blood, then you will be offered the option of withdrawing from the test at that time. If some tests have already been done when you change your mind, we will still use the data from them unless you tell us not to.

For more information you may contact:

Prof Ameena Goga: +27 12 339 8524 or [Ameena.Goga@mrc.ac.za](mailto:Ameena.Goga@mrc.ac.za)

If you have any additional queries, please contact the SAMRC Human Research Ethics committee: Adri Labuschagne, tel. (021) 938 0687; e-mail: [adri.labuschagne@mrc.ac.za](mailto:adri.labuschagne@mrc.ac.za)

## CONSENT TO PARTICIPATE IN A STUDY: ASYMPTOMATIC CONTACTS

### **TITLE: Investigating Point of Care Diagnostic Strategies to Optimise the Rapid Diagnosis of COVID-19 in routine public and private health care settings in South Africa (SA COVID-19 POC STUDY)**

The content of this document and the study has been explained to me, before signing. I have been given the opportunity to ask questions and am satisfied that they have been answered satisfactorily.

I understand that if I do not participate, I can still access testing, treatment and care at the local clinic or hospital. I hereby volunteer to take part in this study.

Consent	Yes	No
I have been informed that this study is about developing better ways to diagnose COVID-19		
I consent to participate in this study		
I agree to answer questions to understand more about the COVID-19 disease		
I agree for my naso-pharyngeal specimens to be used for this study		
I agree to give blood for rapid antibody tests for COVID-19 diagnosis		
I agree to give blood specimens and for my blood specimens to be used to check for immune responses to COVID-19		
I agree to my blood specimens being used for formal antibody testing / neutralisation assays in the laboratory		
I agree to giving nasal swabs for rapid antigen testing for COVID-19		
I agree to be contacted for further follow up		
I agree to giving a saliva specimen		
I agree to be contacted if I am tested positive for further follow-up		
I agree to my specimens being stored for additional testing such as advanced immune system responses to COVID-19, determining how COVID-19 effects my blood and structure/genetics of the virus causing COVID-19.		
I agree that the study team can access my results from the NHLS including my routine SARS-CoV-2 result and any other relevant blood results		

Participant Name

Participant Signature

Date

Staff Conducting IC

Staff Signature

Date

\*Witness Name

\*Witness Signature

Date

\* Witness name, signature and date are required on this consent form only when the consenting participant is not able to read (illiterate)

*It has been explained in full to me why my right to confidentiality and to privacy may be*

English: Study Informed Consent-Asymptomatic, Version 5.0 Dated: 31 March 2021

Based on Protocol: Investigating Point of Care Diagnostic Strategies to Optimize the Rapid Diagnosis of COVID-19 in routine public and private health care settings in South Africa- SA COVID-19 POC STUDY, Version 5.0, Dated: 31 March 2021  
Investigator Ameena Goga

Approved by: SAMRC Human Research Ethics Committee Approved on: 08 April 2021

*limited in respect to the Department of Health.*

*Signed*\_\_\_\_\_

English: Study Informed Consent-Asymptomatic, Version 5.0 Dated: 31 March 2021

Based on Protocol: Investigating Point of Care Diagnostic Strategies to Optimize the Rapid Diagnosis of COVID-19 in routine public and private health care settings in South Africa- SA COVID-19 POC STUDY, Version 5.0, Dated: 31 March 2021

Investigator Ameena Goga

Approved by: SAMRC Human Research Ethics Committee Approved on: 08 April 2021